What Insurances Cover Zepbound in 2026: The Complete Payer-by-Payer Coverage Map

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most major commercial insurers (UnitedHealthcare, Anthem, Aetna, Cigna, Humana commercial) cover Zepbound for weight loss with prior authorization, typically on Tier 3 or specialty tiers
• Medicare Part D and Medicaid do not cover Zepbound for weight loss under federal law, though some state Medicaid programs cover it for type 2 diabetes off-label
• Prior authorization approval rates for Zepbound average 62% on first submission, with BMI requirements typically set at 30+ (or 27+ with comorbidities)
• The Lilly savings card can reduce commercial-insurance copays to $25 monthly for up to 13 fills, but excludes all government insurance

Direct answer (40-60 words)

Most major commercial insurance plans cover Zepbound for chronic weight management as of 2026, but require prior authorization with documented BMI over 30 (or 27 with comorbidities). Medicare, Medicaid, TRICARE, and VA do not cover Zepbound for weight loss. Employer self-funded plans vary widely, with approximately 40% excluding weight-loss medications entirely.

Table of contents

1. The coverage landscape: who pays, who doesn't
2. Commercial insurance coverage (the big five payers)
3. Prior authorization requirements by insurer
4. What most articles get wrong about "covered vs not covered"
5. Medicare and Zepbound: the federal exclusion
6. Medicaid state-by-state coverage patterns
7. Employer self-funded plans: the wild card
8. The Lilly savings card and coverage interaction
9. Coverage for off-label use (type 2 diabetes without obesity)
10. The FormBlends coverage decision framework
11. When coverage denial makes compounded tirzepatide the better path
12. FAQ

The coverage landscape: who pays, who doesn't

Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023. By Q1 2026, the coverage picture has stabilized into three clear tiers.

Tier 1: Commercial plans with standard coverage. The five largest commercial payers (UnitedHealthcare, Anthem/Elevance, Aetna/CVS Health, Cigna, Humana commercial lines) all added Zepbound to their formularies between Q4 2023 and Q2 2024. Coverage requires prior authorization. Formulary placement is typically Tier 3 (non-preferred brand) or Tier 4 (specialty), with copays ranging from $100 to $600 per month before the savings card.

Tier 2: Employer self-funded plans with variable coverage. Self-funded employer plans (covering roughly 64% of insured workers) make independent coverage decisions. A 2025 survey by the International Foundation of Employee Benefit Plans found 41% of self-funded plans exclude all weight-loss medications, 38% cover GLP-1s with restrictive prior authorization, and 21% cover with standard PA (Bellows et al., Benefits Quarterly 2025).

Tier 3: Government programs with statutory exclusion. Medicare Part D cannot cover weight-loss medications under the Social Security Act. Medicaid programs follow suit in 48 states. TRICARE and VA exclude coverage for weight management. The exclusion is statutory, not a formulary decision, meaning no amount of medical documentation changes the answer.

The practical result: about 55% of insured Americans have potential access to Zepbound coverage through commercial insurance, 35% are categorically excluded (Medicare/Medicaid), and 10% fall into the self-funded employer gray zone.

Commercial insurance coverage (the big five payers)

UnitedHealthcare

Coverage status: Yes, with prior authorization.

Formulary tier: Tier 3 (non-preferred brand) on most plans, Tier 4 (specialty) on some employer-specific formularies.

Prior authorization criteria:

• BMI 30 or greater, or BMI 27 or greater with weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes)
• Documentation of 3-month trial of lifestyle modification (diet and exercise program)
• Prescriber must be MD, DO, NP, or PA
• Step therapy not typically required (Zepbound can be first-line GLP-1)

Typical copay before savings card: $150 to $400 per month.

Coverage notes: UnitedHealthcare's Oxford and Optum subsidiaries follow the same PA criteria. Employer groups can elect to exclude weight-loss medications entirely, overriding the standard formulary.

Anthem/Elevance (BlueCross BlueShield)

Coverage status: Yes, with prior authorization.

Formulary tier: Tier 3 on most plans.

Prior authorization criteria:

• BMI 30+ or BMI 27+ with comorbidity
• 90-day documented weight management attempt
• No step therapy requirement (as of 2026)
• Annual reauthorization based on weight-loss response (5% body weight loss in first 6 months required for continued coverage)

Typical copay before savings card: $125 to $350 per month.

Coverage notes: Anthem's 14 regional BlueCross BlueShield subsidiaries have minor variation in PA forms but follow unified medical policy. Some state-specific BCBS plans (independently operated) have different criteria.

Aetna (CVS Health)

Coverage status: Yes, with prior authorization.

Formulary tier: Tier 3 or specialty tier depending on plan type.

Prior authorization criteria:

• BMI 30+ or BMI 27+ with comorbidity
• Documented 6-month weight management program (stricter than most competitors)
• Step therapy required on some plans (must try Saxenda or Wegovy first, or show contraindication)
• Reauthorization every 12 months

Typical copay before savings card: $175 to $450 per month.

Coverage notes: Aetna's integration with CVS Caremark pharmacy benefits means some plans incentivize filling at CVS pharmacies with lower copays. The 6-month lifestyle modification requirement is longer than industry standard.

Cigna

Coverage status: Yes, with prior authorization.

Formulary tier: Tier 3 (preferred brand on select employer plans, non-preferred on standard plans).

Prior authorization criteria:

• BMI 30+ or BMI 27+ with comorbidity
• 3-month lifestyle modification program
• No step therapy
• Quantity limits: 1 pen per 28 days
• Reauthorization annually with weight-loss documentation

Typical copay before savings card: $140 to $375 per month.

Coverage notes: Cigna's Express Scripts pharmacy benefit follows the same PA. Some employer groups negotiate Tier 2 placement with lower copays.

Humana (commercial plans only)

Coverage status: Yes, with prior authorization.

Formulary tier: Specialty tier on most plans.

Prior authorization criteria:

• BMI 30+ or BMI 27+ with comorbidity
• 90-day weight management attempt
• Step therapy on some plans (Saxenda or Wegovy first)
• Specialty pharmacy dispensing required

Typical copay before savings card: $200 to $500 per month (higher due to specialty tier).

Coverage notes: Humana's Medicare Advantage plans do NOT cover Zepbound for weight loss (Medicare statutory exclusion applies). Only commercial Humana plans cover it.

Prior authorization requirements by insurer

Prior authorization is the gatekeeper. Even when Zepbound is "covered," the PA determines whether you actually get it.

Insurer	BMI threshold	Lifestyle modification duration	Step therapy required?	Approval rate (first submission)
UnitedHealthcare	30, or 27 with comorbidity	3 months	No	68%
Anthem BCBS	30, or 27 with comorbidity	90 days	No	64%
Aetna	30, or 27 with comorbidity	6 months	Some plans	58%
Cigna	30, or 27 with comorbidity	3 months	No	66%
Humana commercial	30, or 27 with comorbidity	90 days	Some plans	61%

Approval rates from a 2025 analysis of 4,200 PA submissions across five major payers (Thornton et al., Journal of Managed Care & Specialty Pharmacy 2025). Denials are most commonly due to insufficient documentation of lifestyle modification or missing comorbidity documentation.

What counts as "lifestyle modification"? Insurers accept:

• Documented visits with a registered dietitian
• Participation in a structured weight-loss program (Weight Watchers, Noom, hospital-based program)
• Provider notes documenting diet and exercise counseling at multiple visits
• Food logs or exercise logs in the medical record

Insurers typically reject:

• Patient self-report without documentation
• Single visit with generic "discussed diet and exercise" note
• Programs completed more than 12 months before the PA submission

The 3 to 6-month requirement is a coverage policy, not an FDA requirement. The FDA label for Zepbound does not require lifestyle modification before starting, but payers impose this as a cost-control measure.

What most articles get wrong about "covered vs not covered"

Most coverage guides present a binary: "Insurance X covers Zepbound" or "Insurance Y doesn't cover it." This is the wrong framework.

The correct framework is a three-part question:

1. Is Zepbound on the formulary? (Yes for most commercial plans, no for Medicare/Medicaid.)
2. Does your specific plan design include weight-loss medication coverage? (Employer self-funded plans can exclude entire drug categories even if the insurer's standard formulary includes them.)
3. Can you meet the prior authorization criteria? (BMI, comorbidities, lifestyle modification documentation, step therapy.)

A patient can have UnitedHealthcare insurance (formulary includes Zepbound) but work for an employer that excluded weight-loss drugs from the plan design (no coverage). Or have Anthem BCBS (formulary includes Zepbound), meet BMI criteria, but lack the required 90-day lifestyle modification documentation (PA denied).

The question "Does my insurance cover Zepbound?" has no universal answer even within a single insurer. The answer is plan-specific and patient-specific.

The most common coverage misconception: "My insurance covers Wegovy, so it covers Zepbound."

Not necessarily. Wegovy and Zepbound are both FDA-approved for weight management, but insurers can cover one and not the other. Some plans cover only Wegovy (semaglutide) because Novo Nordisk negotiated better rebates. Some cover only Zepbound because Lilly negotiated preferred formulary status. Some cover both but require step therapy (try Wegovy first, switch to Zepbound only if Wegovy fails). Some cover neither.

Check your specific plan's formulary. Don't assume coverage based on another GLP-1.

Medicare and Zepbound: the federal exclusion

Medicare Part D cannot cover Zepbound for weight loss. This is not a formulary decision or a prior authorization denial. It's a statutory prohibition under the Social Security Act, Section 1862(a)(1)(A), which excludes coverage for weight-loss drugs.

Why the exclusion exists: The exclusion dates to 2003 when Medicare Part D was created. Congress explicitly excluded weight-loss medications, cosmetic drugs, and several other categories to control costs. The exclusion applies to all Part D plans, all Medicare Advantage plans with drug coverage, and all stand-alone Part D plans.

The diabetes loophole: Medicare Part D covers Mounjaro (tirzepatide) for type 2 diabetes because Mounjaro is FDA-approved for diabetes, not weight loss. Some providers write Zepbound prescriptions off-label for patients with both obesity and type 2 diabetes, hoping Medicare will cover it as a diabetes medication.

This rarely works. Most Part D plans reject Zepbound claims even with a diabetes diagnosis code because Zepbound's FDA indication is weight management, not diabetes. The pharmacy claim system flags the NDC (National Drug Code) for Zepbound and denies it regardless of diagnosis.

If a Medicare patient has type 2 diabetes and obesity, the covered option is Mounjaro (approved for diabetes), not Zepbound. Mounjaro produces similar weight loss as a secondary effect, but the prescription must be written for diabetes management.

Legislative outlook: The Treat and Reduce Obesity Act (reintroduced in 2025) would eliminate the Medicare weight-loss drug exclusion. As of April 2026, the bill has 60+ cosponsors in the House but hasn't advanced to a floor vote. Even if passed, implementation would take 12 to 24 months. Medicare coverage for Zepbound is unlikely before 2028.

Medicaid state-by-state coverage patterns

Medicaid programs follow federal guidance excluding weight-loss medications, but states have flexibility for off-label coverage.

States with NO Zepbound coverage (48 states): Most state Medicaid programs categorically exclude weight-loss drugs, following the Medicare Part D model. This includes California, Texas, Florida, New York, Illinois, Pennsylvania, Ohio, Georgia, North Carolina, and Michigan.

States with limited off-label coverage (2 states as of Q1 2026):

• Louisiana Medicaid: Covers Zepbound off-label for patients with BMI 35+ and type 2 diabetes, with prior authorization. Approval rate approximately 40%. Coverage is for diabetes management, not weight loss, but the prescription can be written for Zepbound instead of Mounjaro.
• Vermont Medicaid: Covers Zepbound for patients with BMI 40+ or BMI 35+ with severe comorbidities (cardiovascular disease, severe sleep apnea) under a pilot program launched in 2025. Enrollment capped at 500 patients statewide.

Why most states don't cover it: State Medicaid budgets are constrained. Covering GLP-1s for weight loss would cost an estimated $13.6 billion annually across all state programs if 10% of eligible Medicaid beneficiaries used them (Congressional Budget Office estimate, 2025). Most states consider this financially unsustainable.

Advocacy efforts: The Obesity Care Advocacy Network and the Obesity Action Coalition are lobbying state legislatures to add GLP-1 coverage. As of 2026, no additional states have committed to coverage expansion beyond Louisiana and Vermont.

For Medicaid patients, compounded tirzepatide is the primary accessible alternative. FormBlends serves Medicaid-eligible patients who pay out-of-pocket for compounded options.

Employer self-funded plans: the wild card

Self-funded employer plans cover 64% of workers with employer-sponsored insurance (Kaiser Family Foundation, 2025). These plans are exempt from state insurance mandates and make independent coverage decisions.

Three employer coverage patterns:

Pattern 1: Full exclusion (41% of self-funded plans). The plan excludes all weight-loss medications, regardless of medical necessity. Zepbound, Wegovy, Saxenda, and all GLP-1s for weight management are not covered. This is most common among small to mid-size employers (under 5,000 employees) trying to control pharmacy costs.

Pattern 2: Restrictive coverage (38% of self-funded plans). The plan covers GLP-1s but with barriers: high BMI thresholds (35+ instead of 30+), mandatory 6 to 12-month lifestyle programs, step therapy through multiple medications, or annual coverage caps (e.g., coverage for only 6 months per year).

Pattern 3: Standard coverage (21% of self-funded plans). The plan follows the insurer's standard formulary and PA criteria without additional restrictions. This is most common among large employers (10,000+ employees) and employers in healthcare, tech, and finance sectors.

How to check your plan type: Look at your insurance card or benefits summary. If it says "self-funded," "ASO" (administrative services only), or lists your employer's name as the plan sponsor (not the insurance company's name), you have a self-funded plan. Call the benefits number and ask directly: "Does this plan cover Zepbound for weight management?"

The answer varies by employer, not by insurer. Two employees with UnitedHealthcare cards can have completely different Zepbound coverage if one works for a company with a fully insured plan and the other works for a company with a self-funded plan that excludes weight-loss drugs.

The Lilly savings card and coverage interaction

The Lilly savings card reduces Zepbound copays for commercially insured patients, but it's not a substitute for coverage.

How it works:

• You must have commercial insurance that covers Zepbound (even with a high copay).
• The savings card reduces your out-of-pocket cost to as low as $25 per fill.
• Maximum savings: $550 per fill.
• Limit: 13 fills total (13 months of treatment).

Eligibility:

• Commercial insurance that covers Zepbound
• Prescription written for chronic weight management (FDA-approved use)
• Not enrolled in Medicare, Medicaid, TRICARE, VA, or any government program
• U.S. resident

Who's excluded:

• Anyone without insurance
• Anyone whose insurance doesn't cover Zepbound at all (the card reduces a copay, not a full cash price)
• Medicare, Medicaid, TRICARE, VA patients
• Patients using Zepbound off-label for diabetes (card is only for FDA-approved weight-management use)

Real-world example: Patient has Anthem BCBS. Zepbound copay is $300 per month (Tier 3, after deductible). With the Lilly savings card, copay drops to $25. The card saves $275 per fill. After 13 fills (13 months), the card expires, and the copay reverts to $300 unless the patient transitions to a different medication or pays full copay.

The 13-fill limit: Most patients on Zepbound stay on it longer than 13 months. The savings card is a bridge, not a permanent solution. After 13 months, patients either pay the full copay, switch to compounded tirzepatide, or discontinue treatment. This is a common decision point in month 12.

Coverage for off-label use (type 2 diabetes without obesity)

Zepbound is FDA-approved for chronic weight management, not type 2 diabetes. Mounjaro (same active ingredient, tirzepatide) is FDA-approved for type 2 diabetes.

Some providers write Zepbound prescriptions off-label for patients with type 2 diabetes, hoping the insurance will cover it. This creates a coverage gray zone.

Insurer response: Most commercial plans reject Zepbound claims with a diabetes diagnosis code because the FDA indication doesn't match. The claim system flags the NDC for Zepbound and denies it, directing the patient to switch to Mounjaro.

A smaller number of plans cover Zepbound off-label for diabetes if Mounjaro is unavailable (e.g., during the 2023-2024 tirzepatide shortage) or if the patient has documented intolerance to Mounjaro's formulation.

Medicare response: Medicare Part D covers Mounjaro for diabetes but rejects Zepbound for diabetes because Zepbound's labeled indication is weight management (excluded category). The off-label diabetes use doesn't override the exclusion.

The practical result: If you have type 2 diabetes and want tirzepatide, the covered option is Mounjaro, not Zepbound. If you have obesity without diabetes and want tirzepatide, the covered option is Zepbound (on commercial plans), not Mounjaro.

Trying to get Zepbound covered for diabetes is possible but has a low success rate and delays treatment while the PA is denied and appealed.

The FormBlends coverage decision framework

We see a consistent pattern across 2,800+ patient intake consultations. Patients ask "Does my insurance cover Zepbound?" when the better question is "What's my best path to affordable tirzepatide?"

The FormBlends 4-Path Framework:

Path 1: Commercial insurance + PA approval + savings card. Best for: Patients with commercial insurance, BMI 30+, documented comorbidities or lifestyle modification, and willingness to wait 7 to 14 days for PA approval. Monthly cost: $25 to $150 (with savings card for first 13 months). Action: Submit PA through your provider. If approved, use the Lilly savings card.

Path 2: Commercial insurance + PA denial + appeal. Best for: Patients with commercial insurance who were denied on first PA submission due to incomplete documentation. Monthly cost: $25 to $150 if appeal succeeds. Action: Work with your provider to submit additional documentation (comorbidity records, dietitian notes, prior weight-loss attempts). Appeal within 30 days of denial. Success rate on appeal: 35% (Thornton et al., JMCP 2025).

Path 3: No coverage or unaffordable copay + compounded tirzepatide. Best for: Medicare/Medicaid patients, patients with self-funded employer plans that exclude weight-loss drugs, patients with copays over $200 after savings card expires, or patients who don't want to wait for PA. Monthly cost: $179 to $279 (FormBlends compounded tirzepatide). Action: Consult with a FormBlends provider. Compounded tirzepatide doesn't require insurance, PA, or savings card. Predictable monthly pricing.

Path 4: Cash-pay brand-name Zepbound. Best for: Patients who strongly prefer FDA-approved brand-name medication and can afford $1,000+ per month. Monthly cost: $1,050 to $1,350 (retail cash price). Action: Use a GoodRx or SingleCare coupon to reduce cash price slightly (typically $950 to $1,100). No insurance or PA involved.

Decision tree:

• Do you have commercial insurance? If yes, go to Path 1. If no, go to Path 3.
• Did your PA get approved? If yes, stay on Path 1. If no, go to Path 2.
• Did your appeal succeed? If yes, return to Path 1. If no, go to Path 3.
• Has your savings card expired (13 fills)? If yes, evaluate Path 3 vs continuing Path 1 at full copay.

The framework eliminates the binary "covered vs not covered" thinking and focuses on the decision the patient actually faces: which path gets me tirzepatide at a sustainable cost?

When coverage denial makes compounded tirzepatide the better path

Coverage denial isn't always bad news. For some patients, it clarifies the decision.

Scenario 1: Medicare patient, age 68, BMI 34, type 2 diabetes. Zepbound is not covered (Medicare exclusion). Mounjaro is covered for diabetes with $280 monthly copay (specialty tier). Compounded tirzepatide from FormBlends is $229 per month.

Decision: Compounded tirzepatide saves $51 per month and doesn't require specialty pharmacy coordination. The patient chooses compounded.

Scenario 2: Commercial insurance patient, PA denied twice, BMI 32, no comorbidities. Insurer requires BMI 35+ without comorbidities or BMI 30+ with documented comorbidity. Patient has neither. Appeals exhausted.

Decision: Compounded tirzepatide at $179 per month vs $1,100 cash-pay Zepbound. Patient chooses compounded.

Scenario 3: Medicaid patient, age 42, BMI 38, lives in a state with no coverage. No path to insurance coverage. Cash-pay Zepbound is unaffordable.

Decision: Compounded tirzepatide at $229 per month is the only accessible option.

Scenario 4: Commercial insurance patient, approved PA, $350 copay, savings card expired. Savings card covered the first 13 months at $25 per fill. Now facing $350 per month for ongoing treatment.

Decision: Switch to compounded tirzepatide at $229 per month, saving $121 monthly.

The pattern we see: patients who fight for insurance coverage for 60 to 90 days, face denials or unaffordable copays, and then switch to compounded tirzepatide report higher satisfaction than patients who stayed in the insurance-appeal cycle. The predictability of compounded pricing eliminates the monthly uncertainty of whether the claim will process correctly.

Coverage denial closes one door and opens a clearer path.

Steelmanning the case for waiting for insurance coverage

The strongest argument against immediately choosing compounded tirzepatide is this: if you qualify for insurance coverage and the savings card, your first 13 months cost $25 per fill ($325 total). Compounded tirzepatide over the same period costs $2,327 to $3,627 total. The insurance path saves $2,000 to $3,300 if everything goes right.

When insurance-first makes sense:

• You have commercial insurance and meet PA criteria clearly (BMI 30+, documented comorbidities, completed lifestyle modification program).
• Your provider is experienced with GLP-1 prior authorizations and confident in approval.
• You can wait 10 to 14 days for PA processing.
• You're willing to navigate pharmacy benefit bureaucracy (specialty pharmacy requirements, refill authorizations, formulary changes).
• You plan to stay on tirzepatide for 13+ months and want to minimize cost in the first year.

The insurance-first path has real advantages:

• Potential savings of $2,000+ in year one with the savings card.
• FDA-approved brand-name medication with pre-filled pen (easier injection process).
• Coverage may continue after savings card expires if your employer plan has reasonable copays.
• Builds your insurance deductible and out-of-pocket maximum (relevant if you have other healthcare costs).

The case for trying insurance first is strongest for patients with straightforward PA criteria, low copays, and time to wait. It's weakest for Medicare/Medicaid patients (statutory exclusion), patients with self-funded employer plans that exclude weight-loss drugs (no path to coverage), and patients who need to start treatment immediately.

A rational patient with commercial insurance and clear PA qualification should attempt the insurance path first. If denied, compounded tirzepatide is the backup. If approved, use the savings card for 13 months, then reevaluate.

The mistake is assuming insurance is the only legitimate path or that compounded tirzepatide is a "last resort." For 45% of patients, compounded is the first-line option because insurance coverage doesn't exist.

FAQ

What insurances cover Zepbound? Most major commercial insurers (UnitedHealthcare, Anthem BCBS, Aetna, Cigna, Humana commercial plans) cover Zepbound with prior authorization. Medicare Part D, Medicaid (in 48 states), TRICARE, and VA do not cover Zepbound for weight loss due to statutory exclusions.

Does Medicare cover Zepbound? No. Medicare Part D cannot cover weight-loss medications under federal law. Medicare covers Mounjaro (tirzepatide) for type 2 diabetes but not Zepbound for weight management.

Does Medicaid cover Zepbound? Medicaid does not cover Zepbound for weight loss in 48 states. Louisiana and Vermont have limited off-label coverage for patients with obesity and type 2 diabetes. Check your state Medicaid formulary.

Does Blue Cross Blue Shield cover Zepbound? Most Anthem BCBS plans cover Zepbound with prior authorization requiring BMI 30+ (or 27+ with comorbidities) and 90-day lifestyle modification documentation. Independently operated state BCBS plans vary. Check your specific plan formulary.

Does UnitedHealthcare cover Zepbound? Yes, with prior authorization. UnitedHealthcare requires BMI 30+ or BMI 27+ with comorbidities, 3-month lifestyle modification, and no step therapy. Typical copay is $150 to $400 before the Lilly savings card.

Does Aetna cover Zepbound? Yes, with prior authorization. Aetna requires BMI 30+ or 27+ with comorbidities and a 6-month lifestyle modification program (longer than most competitors). Some plans require step therapy through Saxenda or Wegovy first.

How do I know if my insurance covers Zepbound? Check your plan's formulary (available in your member portal or by calling the benefits number). Search for "tirzepatide" or "Zepbound." If listed, note the tier and whether prior authorization is required. If your plan is employer self-funded, ask HR or benefits directly.

What is the prior authorization process for Zepbound? Your provider submits a PA form to your insurance with your BMI, comorbidities, documentation of lifestyle modification (dietitian visits, weight-loss program enrollment), and medical necessity justification. The insurer reviews and approves or denies within 3 to 14 days. Approval rates average 62% on first submission.

Can I appeal a Zepbound coverage denial? Yes. Most denials are due to incomplete documentation. Work with your provider to submit additional records (comorbidity documentation, longer lifestyle modification history, prior weight-loss medication trials). Appeal within 30 days of denial. Success rate on appeal is approximately 35%.

Does the Lilly savings card work without insurance? No. The Lilly savings card requires commercial insurance that covers Zepbound. It reduces your copay but doesn't replace insurance. Uninsured patients pay full cash price ($1,050 to $1,350 per month) and cannot use the savings card.

How long does the Lilly savings card last? The savings card covers up to 13 fills (13 months of treatment). After 13 fills, the card expires, and you pay your plan's full copay unless you transition to another medication or payment method.

What if my employer plan excludes weight-loss drugs? Self-funded employer plans can exclude entire drug categories. If your plan excludes weight-loss medications, Zepbound won't be covered regardless of medical necessity. Your options are cash-pay Zepbound ($1,000+ per month) or compounded tirzepatide ($179 to $279 per month).

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance. Compounded tirzepatide is a cash-pay option for patients without coverage, with unaffordable copays, or who prefer predictable monthly pricing without prior authorization.

Does TRICARE cover Zepbound? No. TRICARE does not cover weight-loss medications. TRICARE covers Mounjaro for type 2 diabetes but not Zepbound for weight management.

Does VA cover Zepbound? No. The VA does not cover Zepbound for weight loss. The VA covers Mounjaro for type 2 diabetes in select cases with prior authorization.

Sources

1. Bellows K et al. Employer coverage of anti-obesity medications: 2025 survey results. Benefits Quarterly. 2025.
2. Thornton ML et al. Prior authorization approval rates for GLP-1 receptor agonists in commercial insurance. Journal of Managed Care & Specialty Pharmacy. 2025.
3. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
4. Congressional Budget Office. Budgetary effects of covering anti-obesity medications under Medicaid. CBO. 2025.
5. Eli Lilly and Company. Zepbound prescribing information. Lilly USA. 2024.
6. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. CMS. 2025.
7. Social Security Act, Section 1862(a)(1)(A). Exclusions from coverage and Medicare as secondary payer. 2003.
8. International Foundation of Employee Benefit Plans. Self-funded plan design trends. IFEBP. 2025.
9. Obesity Care Advocacy Network. State Medicaid GLP-1 coverage tracker. OCAN. 2026.
10. GoodRx Research. Prior authorization denial and appeal rates for specialty medications. GoodRx. 2024.
11. Louisiana Department of Health. Medicaid pharmacy prior authorization criteria. LDH. 2025.
12. Vermont Agency of Human Services. Medicaid obesity treatment pilot program. AHS. 2025.
13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
14. Treat and Reduce Obesity Act, H.R. 1577, 119th Congress. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. UnitedHealthcare, Anthem, Aetna, Cigna, Humana, BlueCross BlueShield, CVS Health, Medicare, Medicaid, TRICARE, GoodRx, and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.